The authorization of the FDA was based on the obtained positive results in the international study of phase III, controlled by placebo, SHARP (Sofafenib HCC Assessment Randomized Protocol; “Protocol randomized for the evaluation of sorafenib in CHC”) ( Aloe Vera ) that demonstrated that Nexavar prolongs in a 44% the global sobrelife of the patients of cancer of liver compared with placebo.
Two Nexavar years ago one became the first new medicine against the advanced renal cancer, the drug was developed jointly by Bayer HealthCare Ag and Onyx Pharmaceuticals, Inc.
The hepatocellular carcinoma is the most frequent type of hepatic cancer, and is the person in charge of around 90% of primary the malignant tumors of the liver in adults. ( Protein in diet ) It is the sixth more frequent type of tumor anywhere in the world and the third type of cancer that more deaths causes. Annually they are diagnosed more than 600 thousand new cases anywhere in the world and the incidence increases.
No comments:
Post a Comment